These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 35359159)

  • 1. Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials.
    Aday JS; Heifets BD; Pratscher SD; Bradley E; Rosen R; Woolley JD
    Psychopharmacology (Berl); 2022 Jun; 239(6):1989-2010. PubMed ID: 35359159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychedelics and Psychotherapy.
    Nayak S; Johnson MW
    Pharmacopsychiatry; 2021 Jul; 54(4):167-175. PubMed ID: 33285578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expectancy Effects in Psychedelic Trials.
    Szigeti B; Heifets BD
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2024 May; 9(5):512-521. PubMed ID: 38387698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expectancy in placebo-controlled trials of psychedelics: if so, so what?
    Butler M; Jelen L; Rucker J
    Psychopharmacology (Berl); 2022 Oct; 239(10):3047-3055. PubMed ID: 36063208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blinding and expectancy confounds in psychedelic randomized controlled trials.
    Muthukumaraswamy SD; Forsyth A; Lumley T
    Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1133-1152. PubMed ID: 34038314
    [No Abstract]   [Full Text] [Related]  

  • 6. Psychedelics and Evidence-based Psychotherapy: A Systematic Review with Recommendations for Advancing Psychedelic Therapy Research.
    Leone L; McSpadden B; DeMarco A; Enten L; Kline R; Fonzo GA
    Psychiatr Clin North Am; 2024 Jun; 47(2):367-398. PubMed ID: 38724126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychedelics, placebo effects, and set and setting: Insights from common factors theory of psychotherapy.
    Gukasyan N; Nayak SM
    Transcult Psychiatry; 2022 Oct; 59(5):652-664. PubMed ID: 33499762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ethical and Practical Considerations for the Use of Psychedelics in Psychiatry.
    Barber GS; Dike CC
    Psychiatr Serv; 2023 Aug; 74(8):838-846. PubMed ID: 36987705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences?
    Majić T; Schmidt TT; Gallinat J
    J Psychopharmacol; 2015 Mar; 29(3):241-53. PubMed ID: 25670401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should we be leery of being Leary? Concerns about psychedelic use by psychedelic researchers.
    Kious B; Schwartz Z; Lewis B
    J Psychopharmacol; 2023 Jan; 37(1):45-48. PubMed ID: 36377548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychedelics and the essential importance of context.
    Carhart-Harris RL; Roseman L; Haijen E; Erritzoe D; Watts R; Branchi I; Kaelen M
    J Psychopharmacol; 2018 Jul; 32(7):725-731. PubMed ID: 29446697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors.
    Ponomarenko P; Seragnoli F; Calder A; Oehen P; Hasler G
    J Psychopharmacol; 2023 Jul; 37(7):660-678. PubMed ID: 36855289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychedelic drugs for psychiatric disorders.
    da Costa SC; Oesterle T; Rummans TA; Richelson E; Gold M
    J Neurol Sci; 2022 Sep; 440():120332. PubMed ID: 35841696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modalities of the psychedelic experience: Microclimates of set and setting in hallucinogen research and culture.
    Hartogsohn I
    Transcult Psychiatry; 2022 Oct; 59(5):579-591. PubMed ID: 35818775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The challenges ahead for psychedelic 'medicine'.
    Muthukumaraswamy S; Forsyth A; Sumner RL
    Aust N Z J Psychiatry; 2022 Nov; 56(11):1378-1383. PubMed ID: 35243919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deepening our understanding of psychedelics by expanding psychedelic data collection in the United States National Survey on Drug Use and Health.
    Barnett BS
    J Psychopharmacol; 2022 Oct; 36(10):1097-1099. PubMed ID: 36112818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ethical and legal issues in psychedelic harm reduction and integration therapy.
    Pilecki B; Luoma JB; Bathje GJ; Rhea J; Narloch VF
    Harm Reduct J; 2021 Apr; 18(1):40. PubMed ID: 33827588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychedelic Group Therapy.
    Gasser P
    Curr Top Behav Neurosci; 2022; 56():23-34. PubMed ID: 35091980
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.